Ionizable Lipid Products

666-15 is a potent and selective CREB inhibitor with an IC50 of 81 nM.

Namodenoson (CF-102) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively.

Avasimibe is an oral inhibitor of acyl-Coenzyme A:cholesterol acyltransferase (ACAT) with IC50s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively.

ABX464 is a potent anti-HIV agent. ABX464 inhibits HIV-1 replication in stimulated peripheral blood mononuclear cells (PBMCs) with an IC50 ranging between 0.1 μM and 0.5 μM.

Ellipticine hydrochloride is a potent antineoplastic agent; inhibits DNA topoisomerase II activities.

PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analog, is a FGF21-receptor agonist, suitable for development as a potential treatment for T2DM[1][5].

Fedratinib (TG-101348) is a selective inhibitor of JAK2 with an IC50 of 3 nM, showing 35- and 334-fold selectivity over JAK1 and JAK3, respectively.

ZM39923 is a potent, selective JAK3 inhibitor with pIC50 of 7.1, also potently inhibits human tissue transglutaminase (TGM2) with IC50 of 10 nM; ZM39923 is less potent for EGFR, JAK1 and CDK4 with pIC50 of 5.6, 4.4 and < 5.0, no activity fgor JAK2; alteres TGM2 activity in polyglutamine-expressing Drosophila model of neurodegeneration and is found to improve survival; significantly attenuates CCR7-induced Jak3 phosphorylation in metastatic SCCHN cells.

HC-067047 is a potent and selective TRPV4 antagonist with IC50s of 48 nM, 133 nM, and 17 nM for human, rat, and mouse TRPV4.

kb NB 142-70 is a selective protein kinase D (PKD) inhibitor. Demonstrates a 7-fold increase in inhibition potency as an analog of CID 755673. Reported to demonstrate prominent cytotoxic and anti-proliferative effects in vitro. Additionally noted to inhibit cell migration and invasion in a prostate cancer cell line. kb NB 142-70 is an inhibitor of PKC μ, PKC ν and PKD2. For the detailed information of kb NB 142-70, the solubility of kb NB 142-70 in water, the solubility of kb NB 142-70 in DMSO, the solubility of kb NB 142-70 in PBS buffer, the animal experiment (test) of kb NB 142-70, the cell expriment (test) of kb NB 142-70, the in vivo, in vitro and clinical trial test of kb NB 142-70, the EC50, IC50,and affinity,of kb NB 142-70, For the detailed information of kb NB 142-70, the solubility of kb NB 142-70 in water, the solubility of kb NB 142-70 in DMSO, the solubility of kb NB 142-70 in PBS buffer, the animal experiment (test) of kb NB 142-70, the cell expriment (test) of kb NB 142-70, the in vivo, in vitro and clinical trial test of kb NB 142-70, the EC50, IC50,and affinity,of kb NB 142-70, Please contact DC Chemicals.

For the detailed information of Cytidine, the solubility of Cytidine in water, the solubility of Cytidine in DMSO, the solubility of Cytidine in PBS buffer, the animal experiment（test） (test) of Cytidine, the cell expriment (test) of Cytidine, the in vivo, in vitro and clinical trial test of Cytidine, the EC50, IC50,and Affinity of Cytidine,, please contact DC Chemicals.

CA-4948 is a potent IRAK4/FLT3 inhibtor with anti-tumor activity1.CA-4948 is over 500-fold more selective for IRAK-4 compared to IRAK-1. CA-4948 reduces TNF-α, IL-1β, IL-6 and IL-8 release from TLR-Stimulated THP-1 Cells with an IC50 <250 nM. CA-4948 al

ULK-101 (ULK101) is a potent and selective ULK1 inhibitor with in vitro IC50 of 8.3 nM, inhibits ULK2 with IC50 of 30 nM; reduces Ser15 phosphorylation in a concentration-dependent manner in cell-based assay (EC50=390 nM), which is more potent than SBI-0206965 showing a cellular EC50 of 2.4 uM; displays desirable kinome selectivity profile; suppresses autophagy induction and autophagic flux in response to different stimuli, ULK1 inhibition sensitizes KRAS mutant lung cancer cells to nutrient stress.

Sotrastaurin is a potent pan-PKC inhibitor, with Kis of 0.22 nM, 0.64nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKCθ, PKCβ, PKCα, PKCη, PKCδ and PKCε, respectively.

For the detailed information of Alcaftadine, the solubility of Alcaftadine in water, the solubility of Alcaftadine in DMSO, the solubility of Alcaftadine in PBS buffer, the animal experiment（test） (test) of Alcaftadine, the cell expriment (test) of Alcaftadine, the in vivo, in vitro and clinical trial test of Alcaftadine, the EC50, IC50,and Affinity of Alcaftadine,, please contact DC Chemicals.

FOY 251 is an anti-proteolytic active metabolite camostate (HY-13512), acts as a proteinase inhibitor[1].

STING agonist-1 (G10) is a novel human-specific STING agonist that elicits antiviral activity against emerging Alphaviruses. G10 potently blocks replication of Alphavirus species Venezuelan Equine Encephalitis Virus (VEEV) (IC90 = 24.57 μM).

Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist[1][2].

CYN 154806, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC50 values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively[1][2].

CCG-203971 is a second-generation RhoA/myocardin-related transcription factor A (MRTF-A) inhibitor. CCG-203971 potently targets RhoA/C-activated serum response element (SRE)-luciferase (IC50=6.2 μM).